Celgene International Sárl (CELG) Release: Data Evaluating Clinical Potential of ABRAXANE® (Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at American Society of Clinical Oncology
6/4/2012 2:55:31 PM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced results from a study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer. These results were reported during the 48th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Ill.
comments powered by